Article in Nature Biotechnology about our new name and plans for the future (subscription needed to read full text).
LifeArc splashes out, fuelled by Keytruda (pembrolizumab)
Articles & blogs
Related news
First Treatment Approved under EAMS Developed Using MRC Technology Antibody Humanization Expertise
LifeArc monetises Keytruda® royalty interests to fund further research and investment